|
Galapagos Selects Pre-Clinical Candidate Drug for Cachexia
06 January 2009
Galapagos’ pre-clinical candidate G100192 has demonstrated successful Proof of Concept in animal studies.
|
|
|
|
AVI BioPharma Announces FDA Clearance of IND Applications for Clinical Trials of RNA Therapeutic Agents
31 December 2008
The Company has received verbal clearance from the FDA for its two lead products for Marburg and Ebola virus.
|
|
|
|
LifeCycle Pharma Moves LCP-Tacro™ into Clinical Phase 3
30 December 2008
LifeCycle enrolls the first patient in the clinical trial program for use of LCP-Tacro™ in the prevention of organ rejection in stable kidney transplant patients.
|
|
|
|
King Pharmaceuticals Initiates Phase II Clinical Trial Evaluating T-62 as a Treatment for Neuropathic Pain
29 December 2008
The Phase II clinical trial is a double-blind, placebo-controlled study assessing the analgesic efficacy and safety of T-62 in subjects with postherpetic neuralgia.
|
|
|
|
Supernus Initiates Phase III Clinical Trial for Epliga™ in Refractory Partial Onset Epileptic Seizures
29 December 2008
Once-per-day therapy is designed to improve patient compliance and reduce adverse events as compared with reference product Trileptal®.
|
|
|
|
TransMolecular Receives Orphan Drug Designation for 131I-TM601 for the Treatment of Melanoma
29 December 2008
The drug candidate is currently in a Phase 1/2 clinical trial for the treatment of recurrent malignant melanoma.
|
|
|
|
Alnylam Advances RNAi Therapeutics Pipeline and Files Company’s First Systemic Delivery IND
26 December 2008
The Company has filed an IND for ALN-VSP, an RNAi therapeutic for the treatment of liver cancers.
|
|
|
|
ImmunoCellular Therapeutics’ Cancer Vaccine Demonstrates Immune Response against Brain Cancer in Clinical Trial
26 December 2008
Company presents promising clinical data from a Phase I trial evaluating dendritic cell-based cancer vaccine for the treatment of glioblastoma.
|
|
|
|
RegeneRx Updates Schedule for Release of Clinical Trial Information
26 December 2008
The Company will report on its two Phase II ulcer trials evaluating RGN-137 and a Phase I trial evaluating RGN-352 in mid-January, February, March 2009 respectively.
|
|
|
|
Provectus Pharmaceuticals Adds Seventh Center to Phase 2 Clinical Trial of PV-10
26 December 2008
The expansion of Phase 2 trial for metastatic melanoma continues to University of Louisville.
|
|
|
|
Common Treatment for Chronic Prostatitis Fails to Reduce Symptoms
23 December 2008
According to a clinical trial sponsored by the NIDDK, Alfuzosin failed to significantly reduce symptoms in recently diagnosed men having chronic prostatitis.
|
|
|
|
Drais Pharmaceuticals and Diatos Partner to Develop and Commercialize DTS-108 for Treatment of Cancer
23 December 2008
DTS-108 is currently ready to begin Phase I clinical trials in Europe for the treatment of patients with advanced or metastatic solid tumors.
|
|
|
|
Mouse Studies Show Gene Therapy Method Holds Promise in Targeting Tumor Blood Vessels for Destruction
22 December 2008
Researchers develop a method for delivering a therapeutic gene to the blood vessels of tumors in mice that damages the blood vessels and disrupts the blood flow to tumors.
|
|
|
|
Baxter Receives EMEA Positive Opinion for CELVAPAN, the First Cell Culture-Based Pandemic Flu Vaccine
19 December 2008
Clinical data from a Phase III and subsequent booster study demonstrate safety, immune response and cross-protective memory.
|
|
|
|
Pfizer and Celldex Announce Amendment to ACT III Study of CDX-110 in Glioblastoma Multiforme
19 December 2008
The ACT III study will provide a multi-center non-randomized dataset for CDX-110 in patients with newly diagnosed GBM.
|
|
|
|
StemCells Inc. Receives FDA Approval to Initiate Clinical Trial of HuCNS-SC® Cells in a Myelin Disease
19 December 2008
The Phase I trial is designed to evaluate the safety and preliminary efficacy of HuCNS-SC cells as a treatment for Pelizaeus-Merzbacher Disease.
|
|
|
|
Sucampo Initiates Phase 1 Study of SPL-017 for Peripheral Arterial Disease
19 December 2008
The randomized, double-blind, placebo-controlled, single-center, single ascending dose study will evaluate the safety and pharmacokinetic profile of SPL-017.
|
|
|
|
FDA Signs Contract with Entelos to Predict Cardiovascular Adverse Events
18 December 2008
FDA to use the Entelos® Cardiovascular PhysioLab® to assess the cardiovascular safety and efficacy of a specific drug class and a set of drugs within that class.
|
|
|
|
Horizon Discovery Sign Screening Agreement with Actelion Pharmaceuticals
18 December 2008
The agreement covers the screening of a number of Actelion lead compounds on a wide panel of genotypes using Horizon’s X-MAN cell-line technology.
|
|
|
|
NIH Expands Open-Access Dataset of Genetic and Clinical Data to Include Asthma
16 December 2008
The action creates largest public access collection of asthma clinical and genetic data.
|
|
|
|
New Data Show Zometa® Enhances Impact of Chemotherapy on Reducing Breast Tumor Size
15 December 2008
Adding Zometa to chemotherapy prior to surgery led to an additional 33% reduction in tumor size, resulting in fewer mastectomies.
|
|
|
|
Oncolytics Biotech REOLYSIN® Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
15 December 2008
The Phase 2 clinical trial has evaluated the intravenous administration of REOLYSIN® in patients with various sarcomas that have metastasized to the lung.
|
|
|
|
VIVUS Initiates Avanafil Phase 3 Trials in Males with ED
15 December 2008
The REVIVE study is a randomized, double-blind, placebo-controlled, efficacy and safety study of avanafil in men with a history of ED.
|
|
|
|
MorphoSys Announces Second Clinical Milestone in Therapeutic Antibody Program
12 December 2008
MorphoSys and Centocor have enrolled a patient in a Phase 2 clinical trial with a HuCAL-derived fully human antibody.
|
|
|
|
AFFiRiS Begins Development of a Parkinson's Vaccine
12 December 2008
AFFiRiS starts pre-clinical development of its first Parkinson's vaccine that will be investigated for efficacy in Parkinson models.
|
|
|
|
Human Genome Sciences Announces Albuferon® Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
11 December 2008
Albuferon met its primary endpoint of non-inferiority to Pegasys in the ACHIEVE 2/3 trial in patients with genotypes 2 and 3 chronic hepatitis C.
|
|
|
|
Phosphagenics Announce Positive Phase 1 Clinical Trial Results for Transdermal Lidocaine
11 December 2008
The trial demonstrates increased dermal penetration of TPM/Lidocaine compared to topical anaesthetic Xylocaine®.
|
|
|
|
A Novel Human Stem Cell-Based Model of ALS Opens Doors for Rapid Drug Screening
10 December 2008
A study at the Salk Institute confirmed that dysfunctional human astrocytes turn against their charges and kill off healthy motor neurons.
|
|
|
|
Palatin Technologies Announces Extension of Research Collaboration and License Agreement with AstraZeneca
10 December 2008
Both companies enter into clinical trial sponsored research agreement to conduct a study of the effects of melanocortin receptor specific compounds.
|
|
|